Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Aug;15(8):856-869.
doi: 10.1016/j.jiph.2022.06.013. Epub 2022 Jun 23.

Persistent neurological manifestations in long COVID-19 syndrome: A systematic review and meta-analysis

Rizaldy Taslim Pinzon  1 , Vincent Ongko Wijaya  2 , Abraham Al Jody  3 , Patrick Nalla Nunsio  3 , Ranbebasa Bijak Buana  3
Affiliations
Meta-Analysis

Persistent neurological manifestations in long COVID-19 syndrome: A systematic review and meta-analysis

Rizaldy Taslim Pinzon et al. J Infect Public Health. 2022 Aug.

Abstract

Background: Several studies have reported prolonged symptoms especially neurological symptoms following acute infection in patients with COVID-19, known as long COVID-19. There are only few studies investigating this population and relatively less known, including nervous system involvement. A systematic review and meta-analysis of these studies are required to understanding the prevalence of persistent neurological manifestations after COVID-19.

Objective: To conduct a systematic review and meta-analysis on the persistent neurological manifestations in COVID-19 survivors.

Methods: Authors conducted a literature search through PubMed and MedRxiv from January 1st, 2020 to October 2021 according to PRISMA guideline. Furthermore, the authors added additional sources by reviewing related references. Studies presenting the neurologic features of long COVID-19 patients in their data were included. Case reports and case series also included in this review. The quality of the studies was assessed based on the Oxford Centre for Evidence-Based Medicine guidelines. Selected studies were included in the meta-analysis of proportion and heterogeneity test.

Findings: From 128 identified studies, 36 were eligible, with 9944 participants included. Most of the included studies had mean duration of follow-up after COVID-19 onset of less than 6 months. Fatigue was the most common (52.8%, 95%CI 19.9 - 84.4) symptoms of long COVID, followed by cognitive disorder (35.4%, 95%CI 2.1 - 81.7); paresthesia (33.3%, 95%CI 2.7 - 76.6); sleep disorder (32.9%, 95%CI 6.5 - 67.4); musculoskeletal pain (27.8%, 95%CI 12.7 - 46); and dizziness (26.4%, 95%CI 4.6 - 57.9).

Conclusion: Neurological manifestations are prevalent and persisting in patients with long COVID. The duration of the symptoms are vary among literatures. However, the frequency are mostly observed during the first six months after the illness onset.

Keywords: Long covid; Manifestation; Neurology.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Authors have no conflict of interest to disclose, including personal relationships, financial or otherwise.

Figures

Fig. 1
Fig. 1
Search Algorithm for Reviewed Articles.
Fig. 2
Fig. 2
Proportion estimates of Fatigue in long COVID-19 patients.
Fig. 3
Fig. 3
Proportion estimates of Cognitive disorder in long COVID-19 patients.
Fig. 4
Fig. 4
Proportion estimates of Paresthesia in long COVID-19 patients.
Fig. 5
Fig. 5
Proportion estimates of Sleep disorder in long COVID-19 patients.
Fig. 6
Fig. 6
Proportion estimates of Musculoskeletal Pain in long COVID-19 patients.
Fig. 7
Fig. 7
Proportion estimates of Dizziness in long COVID-19 patients.
Fig. 8
Fig. 8
Proportion estimates of Headache in long COVID-19 patients.
Fig. 9
Fig. 9
Proportion estimates of Dysnosmia in long COVID-19 patients.
Fig. 10
Fig. 10
Proportion estimates of Dysgeusia in long COVID-19 patients.
Fig. 11
Fig. 11
Proportion estimates of Movement disorder in long COVID-19 patients.
See this image and copyright information in PMC

References

    1. World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic. World Health Organization (WHO);2020. Available from:https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
    1. Kang S., Peng W., Zhu Y., Lu S., Zhou M., Lin W., et al. Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment. Int J Antimicrob Agents. 2020;55(5) 〈〉 - PMC - PubMed
    1. Liu K., Fang Y.Y., Deng Y., Liu W., Wang M.F., Ma J.P., et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 2020;133(9):1025–1031. - PMC - PubMed
    1. Wang H.Y., Li X.L., Yan Z.R., Sun X.P., Han J., Zhang B.W. Potential neurological symptoms of COVID-19. Ther Adv Neurol Disord. 2020;13. De Felice FG, Tovar-Moll F, Moll J, Munoz DP, Ferreira ST. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the central nervous system. Trends Neurosci. 2020;43(6):355–357. - PMC - PubMed
    1. Needham E.J., Chou S.H., Coles A.J., Menon D.K. Neurological implications of COVID-19 infections. Neurocrit Care. 2020;32(3):667–671. - PMC - PubMed